Original Articles

The Association of Serum Hepcidin Levels and Insulin Resistance in PCOS Patients: A Case-Control Study

Abstract

Objective: To investigate the relationship between insulin resistance and hepcidin levels in patients
with PCOS.
Materials and methods: In this case–control study fifty- six patients with PCOS and forty – one healthy control subjects were included. Plasma levels of hepcidin, IL-6, Serum Insulin and ferritin using ELISA method, serum iron levels using a spectrophotometric method, and Insulin resistance by using HOMA  were measured in the two groups of PCOS (case group) and  healthy subjects (control group). The results were analyzed by student’s t-test, General Linear Model, Binary logistic and linear regression tests.
Results: The mean hepcidin level was 1.97 ± 0.53 pg/ml and 2.40 ± 0.25pg/ml in the case and control groups, respectively. The t-test results showed a significant difference between the two groups
(p = 0.0001). The mean of insulin level in case and control group was 30.65 ± 15.02g/dl and
14.71 ± 10.46g/dl, respectively. The t-test analysis indicated a significant difference between the two groups (p = 0.0001). There was an inverse relationship between the level of hepcidin with HOMA-IR
(β = -0.629, p = 0.04), and IL-6 (β = -0.243, p = 0.015) in both groups. The adjusted OR proved a statistically significant association between serum hepcidin (OR = 0.063; 95 % CI: 0.01-0.385,
p-value  =  0. 003) and HOMA (OR  =  1.569; 95 % CI: 1.254–1.964, p-value  =  0.001) with PolycysticOvarian Syndrome.
Conclusion: There was an inverse relationship between hepcidin levels and insulin resistance in both groups meaning decrease in hepcidin levels and increase in insulin resistance may increase the risk of PCOS.

1. Kumarapeli V, SeneviratneRde A, Wijeyaratne CN, Yapa RM, Dodampahala SH. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka. Am J Epidemiol 2008; 168:321-8.
2. Duncan WC. A guide to understanding polycystic ovary syndrome (PCOS). J Fam Plann Reprod Health Care 2014; 40: 217-25.
3. Çakıroğlu Y, Vural F, Vural B. The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. J Endocrinol Invest 2016;39: 899-907.
4. Williams T, Mortada R, Porter S. Diagnosis and Treatment of Polycystic Ovary Syndrome. Am Fam Physician 2016; 94:106-13.
5. Polak K, Czyzyk A, Simoncini T, Meczekalski B. New markers of insulinresistance in polycystic ovary syndrome. J Endocrinol Invest. 2017;40:1-8.
6. Cree-Green M, Rahat H, Newcomer BR, Bergman BC, Brown MS, Coe GV, Newnes L, Garcia-Reyes Y, Bacon S, Thurston JE, Pyle L, Scherzinger A, Nadeau KJ. InsulinResistance, Hyperinsulinemia, and Mitochondria Dysfunction in Nonobese Girls With Polycystic Ovarian Syndrome. J Endocr Soc 2017;1:931-44.
7. Morgante G, Cappelli V, Di Sabatino A, Massaro MG, De Leo V. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.Minerva Ginecol 2015;67:457-63.
8. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What's new? Adv Clin Exp Med 2017; 26: 359-67.
9. Luque-Ramírez M, Álvarez-Blasco F, Alpañés M, Escobar-Morreale HF. Role ofdecreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2011;96:846-52.
10. Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 2009;73:527-36.
11. Wang H, Li H, Jiang X, Shi W, Shen Z, Li M. Hepcidin is directly regulated by insulin and plays an important role in iron overload in streptozotocin-induced diabetic rats. Diabetes 2014; 63:1506-18.
12. Vela D, Leshoski J, Gjorgievska ES, Hadzi-Petrushev N, Jakupaj M, Sopi RB,et al. The Role of Insulin Therapy in Correcting Hepcidin Levels in Patients with Type 2 Diabetes Mellitus. Oman Med J 2017; 32:195-200.
13. Sam AH, Busbridge M, Amin A, Webber L, White D, Franks S, et al. Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. Diabet Med 2013; 30: 1495-9.
14. Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Sanchón R, San MillánJL, Escobar-Morreale HF. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 2007; 30:2309-13.
15. Datz C, Felder TK, Niederseer D, Aigner E. Iron homeostasis in the metabolic syndrome. Eur J Clin Invest 2013; 43:215-24.
16. Insenser M, Martínez-García MA, Montes R, San-Millán JL, Escobar-Morreale HF. Proteomic analysis of plasma in the polycystic ovary syndrome identifies novelmarkers involved in iron metabolism, acute-phase response, and inflammation. J Clin Endocrinol Metab 2010;95:3863-70.
17. Xu X, Du C, Zheng Q, Peng L, Sun Y. Effect of metformin on serum interleukin-6 Levels in polycystic ovary syndrome: a systematic review. BMC Womens Health 2014; 14:93.
18. Ahmed HH, Fadl NN, Kotob SE. Impact of Long Term Metformin Therapy on Hepcidin and Iron Status in Type II Diabetic Patients. International Journal of Pharmaceutical and Clinical Research2015; 7:185-93.
19. Fernández-Real JM, Equitani F, Moreno JM, Manco M, Ortega F, Ricart W. Study Of circulating prohepcidin in association with insulin sensitivity and changing Iron stores. J Clin Endocrinol Metab2009; 94:982-8.
20. Ambachew S, Biadgo B. Hepcidin in Iron Homeostasis: Diagnostic and Therapeutic Implications in Type 2 Diabetes Mellitus Patients. Acta Haematol 2017; 138: 183-93.
21. Martínez-García MA, Luque-Ramírez M, San-Millán JL, Escobar-Morreale HF. Body iron stores and glucose intolerance in premenopausal women: role ofhyperandrogenism, insulin resistance, and genomic variants related toinflammation, oxidative stress, and iron metabolism. Diabetes Care 2009; 32:1525-30.
22. HosseinRashidi B, Shams S, Shariat M, KazemiJaliseh H, Mohebi M, Haghollahi F. Evaluation of serum hepcidin and iron levels in patients with PCOS: a case-control study. J Endocrinol Invest 2017; 40: 779-84.
23. Kim JW, Kang KM, Yoon TK, Shim SH, Lee WS. Study of circulating hepcidin in association with iron excess, metabolic syndrome, and BMP-6 expression in granulosa cells in women with polycystic ovary syndrome. Fertil Steril 2014;102:548-54.e2.
24. Ko PC, Huang SY, Hsieh CH, Hsu MI, Hsu CS. Serum ferritin levels and Polycystic ovary syndrome in obese and non-obese women. Taiwan J Obstet Gynecol.2015; 54:403-7.
25. Sangkhae V, Nemeth E. Regulation of the Iron Homeostatic Hormone Hepcidin. Adv Nutr 2017; 8:126-36.
26. Escobar-Morreale HF. Iron metabolism and the polycystic ovary syndrome. Trends Endocrinol Metab 2012;23:509-15.
27. Briones L, Andrews M, Pizarro F, Arredondo-Olguín M. Expression of genesassociated with inflammation and iron metabolism in 3T3-L1 cells induced withmacrophages-conditioned medium, glucose and iron. Biometals 2018; 31: 595-604.
28. Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol 2009; 46:387-93.
29. Vela D. Hepcidin, an emerging and important player in brain iron homeostasis. J Transl Med 2018; 16:25.
30. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidintranscription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 2005; 102:1906-10.
31. Wang SM, Fu LJ, Duan XL, Crooks DR, Yu P, Qian ZM, et al. Role of hepcidin in murine brain iron metabolism. Cell Mol Life Sci 2010;67:123-33.
Files
IssueVol 12, No 4 (December 2018) QRcode
SectionOriginal Articles
Keywords
PCOS Hepcidin Serum Insulin Insulin Resistance
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Rashidi B, Shams S, Shariat M, Bagheri M, Mohebi M, Haghollahi F. The Association of Serum Hepcidin Levels and Insulin Resistance in PCOS Patients: A Case-Control Study. J Family Reprod Health. 2018;12(4):210-216.